Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers
Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, single dose, dose-escalation study to evaluate the
safety, tolerability, and pharmacokinetics of NCTX (PEGylated Liposomal Iodixanol Injection)
administered intravenously to healthy volunteers. In addition, computed tomography (CT) scans
will be acquired to measure radiographic density in regions of interest (ROI) at times from
3-5 hours and up to 72 hours following NCTX administration.